SCHEMBL23211739

SCHEMBL23211739

O=C(O)N1CCC(C(c2ccc(F)cc2)c2nc(C3CC3)no2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.38
DPP9 Q86TI2 3/20 0.38
DPP7 Q9UHL4 3/20 0.38
KCNH2 Q12809 2/20 0.38
DPP8 Q6V1X1 2/20 0.38
SLC6A3 Q01959 1/20 0.38
DGKA P23743 3/20 0.37
DGKZ Q13574 3/20 0.37
SCD5 Q86SK9 1/20 0.37
TSHR P16473 2/20 0.36
LMNA P02545 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
CACNA1B Q00975 2/20 0.36
POLB P06746 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
IDO1 P14902 1/20 0.36
LDHA P00338 1/20 0.35
PRCP P42785 2/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23211817 0.85 MMP13 (0.47) DPP4LMNAMAPK1POLB
SCHEMBL21381594 0.85 MMP13 (0.47) DPP4LMNAMAPK1POLB
SCHEMBL23211877 0.84 SLC6A3 (0.43) DPP4DPP9DPP7KCNH2DPP8
SCHEMBL21381650 0.79 SLC6A3 (0.51) DPP4DPP9DPP7KCNH2DPP8
Hydrochloric Acid SCHEMBL21382129 0.78 USP7 (0.39) SLC6A3DGKADGKZ
SCHEMBL23212025 0.78 MGLL (0.59)
SCHEMBL21390374 0.78 MGLL (0.59)
SCHEMBL30149607 0.78 MGLL (0.59)
SCHEMBL27151212 0.77 MGLL (0.44) DGKADGKZIDO1PRCP
SCHEMBL27150722 0.77 MGLL (0.44) DGKADGKZIDO1PRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-3768684-B1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN LA ROCHE (CH) 2023-02-22 EP disclosed
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210107920-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC DPP4 542/4885DPP9 426/4885DPP7 730/4885
US-20230117324-A1 OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS MGLL, LPL, LIPC DPP4 542/4885DPP9 426/4885DPP7 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.